INFO & CONTACTS:  +39 02 2390 1

A phase I study to evaluate the safety and preliminary signs of efficacy of [177Lu]Lu-OncoFAP-23 alone or in combination with L19-IL2 as a treatment of metastatic FAP-positive solid tumors

Phase: Phase I clinical trials

Main Facility: Medicina Nucleare

Drug: [68Ga]Ga-OncoFAP (OncoFAP-DOTAGA marcato con 68Ga)

[177Lu]Lu-OncoFAP-23 (OncoFAP-23 marcato con 177Lu)

L19-IL2

Pathologies: Advanced Solid Tumours

The primary objective of this study is to assess the safety of [177Lu]Lu-OncoFAP-23 alone or in combination with L19-IL2 for the treatment of advanced/metastatic FAP-positive solid tumors and to establish a Recommended Dose (RD).

Last update: 20/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe